NCT04274023View on ClinicalTrials.gov

Study on TSR-042 in Advanced Clear Cell Sarcoma

PHASE2TerminatedINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

January 29, 2024

Primary Completion Date

January 29, 2024

Study Completion Date

January 29, 2024

Conditions
Sarcoma, Clear Cell
Interventions
DRUG

TSR-042

TSR-042 is an IgG4 humanized monoclonal antibody that binds with high affinity to PD-1, resulting in inhibition of binding to PD-L1 and PD-L2.

Trial Locations (1)

20133

Fondazione IRCSS Istituto Nazionale dei Tumori, Milan

Sponsors

Collaborators (1)

GlaxoSmithKline
All Listed Sponsors
collaborator

GlaxoSmithKline

INDUSTRY

lead

Italian Sarcoma Group

NETWORK

NCT04274023 - Study on TSR-042 in Advanced Clear Cell Sarcoma | Biotech Hunter | Biotech Hunter